Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma

被引：0
|
作者：
Gil-Fernandez, Juan Jose [1 ,2 ]
Ramirez, Patricia Garcia [1 ]
Charavia, Marta Callejas [1 ]
机构：
[1] Univ Hosp Principe Asturias, Hematol Dept, Alcala De Henares, Spain
[2] Univ Hosp Principe Asturias, Hematol Dept, HU Principe Asturias, Madrid 28805, Spain
来源：
CLINICAL CASE REPORTS | 2024年 / 12卷 / 01期
关键词：
daratumumab-refractory myeloma; first-line therapy; isatuximab post daratumumab; newly diagnosed multiple myeloma;
D O I：
10.1002/ccr3.8449
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)
    Costa, Luciano
    Chhabra, Saurabh
    Medvedova, Eva
    Dholaria, Bhagirathbhai
    Schmidt, Timothy
    Silbermann, Rebecca
    Godby, Kelly
    Dhakal, Binod
    Bal, Susan
    Giri, Smith
    D'Souza, Anita
    Cornell, Robert
    Hardwick, Pamela
    Omel, James
    Hari, Parameswaran
    Callander, Natalie S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S33 - S33
  • [22] Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis
    An, Gang
    Liu, Zhuogang
    Jin, Jie
    Cai, Zhen
    Li, Wei
    Xia, Zhongjun
    Cen, Xinan
    Hu, Yu
    Mi, Jian-Qing
    Jing, Hongmei
    Zhan, Rong
    Qu, Xiaoyan
    Du, Xin
    Gao, Dan
    Zhao, Liang
    Qiu, Lugui
    BLOOD, 2024, 144 : 7055 - 7056
  • [23] Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes
    Kumar, Shaji K.
    Laplant, Betsy
    Asmus, Erik J.
    Buadi, Francis K.
    Gonsalves, Wilson, I
    Muchtar, Eli
    Dingli, David
    Thompson, Melanie Ann
    Go, Ronald
    Warsame, Rahma M.
    Kourelis, Taxiarchis
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Leung, Nelson
    Binder, Moritz
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kapoor, Prashant
    BLOOD, 2022, 140 : 10142 - 10143
  • [24] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase Ill study (CEPHEUS)
    Zweegman, Sonja
    Usmani, Saad Zafar
    Chastain, Katherine
    Carey, Jodi
    Ren, Karen
    Smith, Elena
    Krevvata, Maria
    Wang, Jianping
    Vermeulen, Jessica
    Facon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
    Loncharich, Alexa J.
    Fiala, Mark A.
    Slade, Michael J.
    Vickroy, Angela
    Kavanaugh, Margaret
    Wilson, Carmen
    Schroeder, Mark A.
    Stockerl-Goldstein, Keith
    Vij, Ravi
    Sanfilippo, Kristen M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11): : 825 - 828
  • [26] Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone
    Loncharich, Alexa J.
    Fiala, Mark A.
    Slade, Michael J.
    Vickroy, Angela
    Kavanaugh, Margaret
    Wilson, Kari
    Schroeder, Mark A.
    Stockerl-Goldstein, Keith E.
    Vij, Ravi
    Sanfilippo, Kristen M.
    BLOOD, 2022, 140 : 8550 - 8551
  • [27] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study
    Sborov, Douglas
    Baljevic, Muhamed
    Reeves, Brandi
    Laubach, Jacob
    Efebera, Yvonne
    Rodriguez, Cesar
    Costa, Luciano
    Chari, Ajai
    Silbermann, Rebecca
    Holstein, Sarah
    Anderson, Larry D., Jr.
    Kaufman, Jonathan
    Shah, Nina
    Pei, Huiling
    Patel, Sharmila
    Cortoos, Annelore
    Bartlett, Blake
    Vermeulen, Jessica
    Lin, Thomas
    Voorhees, Peter
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S135 - S136
  • [28] Daratumumab plus Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
    Voorhees, Peter
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano
    Anderson, Larry
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E353 - E354
  • [29] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial
    Jacobus, Susanna J.
    Cohen, Adam D.
    Weiss, Matthias
    Callander, Natalie Scott
    Singh, Avina A.
    Parker, Terri L.
    Menter, Alex R.
    Yang, Xuezhong
    Parsons, Benjamin Marshall
    Kumar, Pankaj
    Kapoor, Prashant
    Rosenberg, Aaron Seth
    Zonder, Jeffrey A.
    Faber, Edward Anthony
    Lonial, Sagar
    Richardson, Paul G.
    Orlowski, Robert Z.
    Wagner, Lynne I.
    Rajkumar, S. Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
  • [30] Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Sauer, Sandra
    Kriegsmann, Katharina
    Nientiedt, Cathleen
    Schmitt, Anita
    Mueller-Tidow, Carsten
    Raab, Marc-Steffen
    Kauer, Joseph
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2023, 50 (05) : 371 - 380
12345